Key terms
About VCYT
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VCYT news
Feb 29
4:44pm ET
Veracyte files automatic mixed securities shelf
Feb 27
7:11am ET
Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
Feb 26
8:04pm ET
Cathie Wood’s ARK Investment bought 154K shares of Veracyte today
Feb 25
11:27pm ET
Veracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst Outlook
Feb 23
7:17am ET
Veracyte price target raised to $33 from $30 at Needham
Feb 23
5:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)
Feb 22
4:29pm ET
Veracyte backs FY24 revenue view of $394M-$402M, consensus $393.3M
Feb 22
4:29pm ET
Veracyte reports Q4 GAAP EPS (39c) vs. (5c) last year
Feb 07
4:13am ET
Veracyte Streamlines Finance with Equity Sales Exemption
Feb 07
4:13am ET
Veracyte Finalizes C2i Genomics Acquisition Deal
Jan 11
1:26am ET
Buy Rating Affirmed for Veracyte Amid Strong Financials and Strategic MRD Market Acquisition
Jan 08
12:16pm ET
Solid Growth and Strategic Acquisition Bolster Buy Rating for Veracyte
Jan 08
8:37am ET
Veracyte to acquire C2i Genomics for $70M upfront
Jan 08
8:35am ET
Veracyte sees FY24 revenue $394M-$402M, consensus $391.5M
Jan 08
8:33am ET
Veracyte sees FY23 revenue $358M-$359M, consensus $352.78M
Jan 08
8:32am ET
Veracyte sees Q4 revenue $95M-$96M, consensus $89.91M
No recent press releases are available for VCYT
VCYT Financials
Key terms
Ad Feedback
VCYT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VCYT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range